Women's Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chelsea & Westminster Hospital, London
HAART efficacy and toxicity widely variable between HIV-infected patients
February 5th, 2006
HAART efficacy and toxicity is widely variable between HIV-infected patients. According to a recent review from England, "As physicians are confronted with a diversity of adverse events and variability in response to medication among patients, this review will focus on the available evidence regarding the impact of genetic variation on drug response. "Specifically, variation in drug metabolizing enzymes such as the cytochrome P450s, drug transporters, and human leukocyte antigen (for idiosyncratic drug reactions). The potential role of pharmacogenetics in the management of HIV-1 infected individuals and drug discovery will be discussed." ...
Source: Women's Health Law Weekly (2006-02-05)
|
